Get the Stockscreener App
1.1998
0.88%
-0.0102
Nrx Pharmaceuticals Inc stock is traded at $1.1998, with a volume of 39,054.
It is down -0.88% in the last 24 hours and down -3.27% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$1.21
Open:
$1.2
24h Volume:
39,054
Relative Volume:
0.32
Market Cap:
$13.06M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-2.1049
EPS:
-0.57
Net Cash Flow:
$-21.66M
1W Performance:
+3.40%
1M Performance:
-3.27%
6M Performance:
-68.93%
1Y Performance:
-59.20%
1-Day Range:
$1.1895
$1.215
1-Week Range:
$1.1299
$1.36
52-Week Range:
$1.10
$7.333
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| NRXP | 1.195 | 13.06M | 0 | -30.15M | -21.66M | -0.57 |
| VRTX | 448.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.39 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.08 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.00 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.80 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Po - GuruFocus.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: NRx Pharmaceuticals projects profitability by 2025 - Investing.com UK
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer - BioSpace
NRx Pharmaceuticals Reports Progress in Drug Development - TipRanks
NRx Pharmaceuticals names Michael Abrams as new CFO - Investing.com
NRx Pharmaceuticals Names Biotech Veteran Michael Abrams as New CFO to Drive Growth | NRXP Stock News - StockTitan
NRXPNRX Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NRX Pharmaceuticals Inc (NRXP) Quarterly 10-Q Report - Quartzy
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update - Yahoo Finance
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NRx Pharmaceuticals delays Q3 results call to November 18 By Investing.com - Investing.com Canada
NRx Pharmaceuticals delays Q3 results call to November 18 - Investing.com
NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024 - XM
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 - Yahoo Finance
NRx Pharmaceuticals (NRXP) Scheduled to Post Earnings on Thursday - Defense World
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 - BioSpace
NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update L - GuruFocus.com
NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule - GlobeNewswire
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq th - GuruFocus.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - StockTitan
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Unde - GuruFocus.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 - GuruFocus.com
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarte - GuruFocus.com
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2 - GuruFocus.com
NRx Pharmaceuticals, Inc. and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - Marketscreener.com
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE - GlobeNewswire
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - StockTitan
EF Hutton Acquisition Co. I Upgrades NRx Pharmaceuticals (NASDAQ:NRXP) to Strong-Buy - Defense World
Can Nrx combination unlock NMDA’s oomph in akathisia? - BioWorld Online
EF Hutton sets stock target on NRx Pharma, cites suicide prevention - Investing.com India
NRx started at buy by EF Hutton, cites suicide prevention focus - MSN
NRx started at buy by EF Hutton, cites suicide prevention focus (NASDAQ:NRXP) - Seeking Alpha
NRx Pharmaceuticals secures additional $5 million funding By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals secures additional $5 million funding - Investing.com India
NRx Pharmaceuticals announces CEO resignation and stockholder votes - Investing.com
NRx Pharmaceuticals announces CEO resignation and stockholder votes By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals Leadership Shift and Strategic Governance Decisions - Yahoo Finance
NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
NRXP stock touches 52-week low at $1.33 amid market challenges - Investing.com
NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding from Streeterville Capital, LLC - Marketscreener.com
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MSN
HOPE Therapeutics and NRx Pharmaceuticals to Acquire a Premier West Coast Interventional Psychiatric Clinic - citybiz
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic - cnhinews.com
NRXP stock touches 52-week low at $1.59 amid market challenges By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Streamlines Operations to Enhance YCANTH Access - MyChesCo
NRXP stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):